Century Therapeutics (NASDAQ:IPSC) Posts Earnings Results, Beats Estimates By $0.08 EPS

Century Therapeutics (NASDAQ:IPSC) announced its quarterly earnings data on Tuesday. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08, RTT News reports. The company had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.47 million. Century Therapeutics had a negative net margin of 6,434.23% and a negative return on equity of 60.60%. During the same period in the prior year, the firm posted ($0.55) EPS.

Century Therapeutics Price Performance

Century Therapeutics stock traded up $0.05 during mid-day trading on Wednesday, hitting $1.38. 379,254 shares of the company were exchanged, compared to its average volume of 259,010. Century Therapeutics has a 12-month low of $1.14 and a 12-month high of $5.51. The business’s 50 day simple moving average is $1.53 and its two-hundred day simple moving average is $2.24. The company has a market capitalization of $116.91 million, a P/E ratio of -0.65 and a beta of 1.41.

Analysts Set New Price Targets

IPSC has been the topic of a number of analyst reports. HC Wainwright lowered their price objective on shares of Century Therapeutics from $9.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday. Rodman & Renshaw started coverage on Century Therapeutics in a report on Thursday, August 8th. They issued a “buy” rating and a $6.00 price target on the stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.